SURI ETF — Holdings & Analysis

The Simplify Propel Opportunities ETF (SURI) is an actively managed equity ETF that aims to provide long-term capital growth by investing in biotech, pharma, health care technology, and life science companies. The fund seeks to identify companies that are believed to be overlooked by investors, presenting significant opportunities for capital appreciation. SURI is sub-advised by Propel, which uses its scientific and commercial expertise in health sciences to identify the most promising health science investment opportunities. As of 2026-03-15, SURI has $0.07 billion in assets under management and a net asset value (NAV) of $16.82.

The expense ratio for the Simplify Propel Opportunities ETF (SURI) is 2.82%. This means that for every $10,000 invested in the fund, investors will pay $282 in annual fees to cover the fund's operating expenses. This expense ratio is significantly higher than the category average for equity ETFs, which is approximately 0.44%. the may be worth researching impact of this higher expense ratio on their overall returns, especially over the long term.

As of 2026-03-15, the top holdings in the Simplify Propel Opportunities ETF (SURI) are: Plains GP Holdings LP Class A (PAGP) at 36.76%, Achieve Life Sciences Inc at 6.92%, Phathom Pharmaceuticals Inc Ordinary shares at 4.93%, Milestone Pharmaceuticals Inc at 3.30%, and Abeona Therapeutics Inc at 3.28%. These top holdings represent a significant portion of the fund's total assets, indicating a concentrated investment strategy. Investors should be aware of the potential impact of these individual holdings on the fund's overall performance.

Whether SURI is a suitable long-term investment depends on an individual investor's risk tolerance, investment goals, and time horizon. SURI offers exposure to biotech, pharma, health care technology, and life science companies, potentially providing growth opportunities. However, the fund's high expense ratio of 2.82% can negatively impact long-term returns. Additionally, SURI's beta of 1.29 indicates higher volatility compared to the overall market. Investors should carefully consider these factors and conduct thorough research before making an investment decision. Past performance does not guarantee future results.

SURI differentiates itself from similar ETFs through its active management and focus on overlooked opportunities within the health sciences sector. Its expense ratio of 2.82% is considerably higher than many passively managed healthcare ETFs. With AUM of $0.07 billion, SURI is relatively small compared to established healthcare ETFs. The fund's strategy of using Propel's scientific expertise to identify investments also sets it apart. Investors should weigh these factors when comparing SURI to other ETFs in the healthcare and biotechnology space.

As of 2026-03-15, the Simplify Propel Opportunities ETF (SURI) has a dividend yield of 0.00%. This indicates that the fund does not currently distribute any dividends to its shareholders. Investors seeking income-generating investments may want to consider other ETFs with a history of dividend payments. However, it is important to note that dividend yields can fluctuate over time and are not guaranteed.